2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
This edition of Year in Review is focused on gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer, and immunotherapy and targeted therapies used in the management of these cancers.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
DKN-01 plus tislelizumab and CAPOX combination demonstrates promising response rates and safety data in phase 2a study.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Results from the CheckMate-648 study demonstrate that nivolumab added to either ipilimumab or chemotherapy improves overall survival in patients with advanced esophageal squamous-cell carcinoma.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Recently released positive findings from the LEAP-005 trial of lenvatinib plus pembrolizumab in the treatment of previously treated gastric cancer leads to cohort expansion.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
No survival advantage was observed with durvalumab use in the PLATFORM clinical trial, but a patient subgroup was observed to have a radiological response.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
The dose-escalation phase of the EMERGE clinical trial results show that 200 mg domatinostat twice daily is safe and efficacious.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Avelumab maintenance therapy conveys no overall survival difference over the use of continued chemotherapy in patients with advanced GEJC or gastric cancer.
© 2009-2021 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512